NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $28.26 +0.10 (+0.36%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$28.16▼$28.6350-Day Range$23.01▼$28.2652-Week Range$22.01▼$32.88Volume1.69 million shsAverage Volume1.88 million shsMarket Capitalization$4.78 billionP/E Ratio11.17Dividend YieldN/APrice Target$36.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside29.9% Upside$36.70 Price TargetShort InterestBearish10.96% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment1.13Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth-5.93%From $2.36 to $2.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.63 out of 5 starsMedical Sector51st out of 924 stocksPharmaceutical Preparations Industry18th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.96% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Alkermes has recently increased by 14.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 2.3 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -5.93% in the coming year, from $2.36 to $2.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 11.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 11.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.56.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.56. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesAugust 22 at 7:00 AM | prnewswire.comAlkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2August 15, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Alkermes plc (NASDAQ:ALKS) Increased by AnalystAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.August 15, 2024 | americanbankingnews.comBrokers Issue Forecasts for Alkermes plc's Q4 2024 Earnings (NASDAQ:ALKS)August 7, 2024 | forbes.comHow This $4.3B Pharma Company Is Helping Underserved Patients in NeuroJuly 28, 2024 | seekingalpha.comAlkermes: Fairly Valued After Post-Earnings BumpJuly 27, 2024 | markets.businessinsider.comStrong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive OutlookJuly 26, 2024 | markets.businessinsider.comMaintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline UncertaintiesAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 25, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)July 25, 2024 | markets.businessinsider.comStrong Performance and Clinical Promise Uphold Buy Rating for Alkermes with $32 Target PriceJuly 25, 2024 | msn.comAlkermes plc (NASDAQ:ALKS) Q2 2024 Earnings Call TranscriptJuly 24, 2024 | finance.yahoo.comIs Alkermes plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals?July 24, 2024 | markets.businessinsider.comAlkermes Lags Q2 Earnings EstimatesJuly 24, 2024 | seekingalpha.comAlkermes plc 2024 Q2 - Results - Earnings Call PresentationJuly 24, 2024 | prnewswire.comAlkermes plc Reports Second Quarter 2024 Financial ResultsJuly 23, 2024 | markets.businessinsider.comAlkermes earnings: here's what Wall Street expectsJuly 17, 2024 | prnewswire.comAlkermes to Report Second Quarter Financial Results on July 24, 2024See More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/24/2024Today8/21/2024Next Earnings (Estimated)10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$36.70 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+29.9%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.53 Trailing P/E Ratio11.17 Forward P/E Ratio11.97 P/E Growth0.56Net Income$355.76 million Net Margins19.15% Pretax Margin20.87% Return on Equity23.20% Return on Assets13.52% Debt Debt-to-Equity Ratio0.22 Current Ratio2.99 Quick Ratio2.61 Sales & Book Value Annual Sales$1.51 billion Price / Sales3.17 Cash Flow$2.39 per share Price / Cash Flow11.84 Book Value$7.80 per share Price / Book3.62Miscellaneous Outstanding Shares169,221,000Free Float160,946,000Market Cap$4.78 billion OptionableOptionable Beta0.47 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.61MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO Comp: $1.17MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.15MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $950.88kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.24MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXAgios PharmaceuticalsNASDAQ:AGIOPacira BioSciencesNASDAQ:PCRXAtea PharmaceuticalsNASDAQ:AVIRADC TherapeuticsNYSE:ADCTView All CompetitorsInsiders & InstitutionsCreative PlanningBought 7,296 shares on 8/16/2024Ownership: 0.020%Algert Global LLCBought 16,191 shares on 8/16/2024Ownership: 0.010%Mackenzie Financial CorpSold 6,308 shares on 8/15/2024Ownership: 0.154%The Manufacturers Life Insurance Company Sold 7,591 shares on 8/15/2024Ownership: 0.119%Susquehanna Portfolio Strategies LLCSold 66,857 shares on 8/15/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.74 on January 1st, 2024. Since then, ALKS stock has increased by 1.9% and is now trading at $28.26. View the best growth stocks for 2024 here. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) posted its earnings results on Wednesday, July, 24th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. The business's quarterly revenue was down 35.4% on a year-over-year basis. Is Alkermes doing a stock buyback? Alkermes' board authorized a share buyback plan on Thursday, February 15th 2024, which permits the company to buy back $400,000,000 in shares, according to EventVestor. This means that the company could buy up to 8.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. Does Alkermes have any subsidiaries? Alkermes subsidiaries include these companies: Rodin Therapeutics. Who are Alkermes' major shareholders? Alkermes' top institutional shareholders include Pacer Advisors Inc. (3.33%), Renaissance Technologies LLC (3.24%), Primecap Management Co. CA (2.00%) and Dimensional Fund Advisors LP (1.70%). Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, Blair Curtis Jackson, Christian Todd Nichols, Nancy Wysenski, Cato T Laurencin, Emily Peterson Alva and Craig C Hopkinson. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX) and This page (NASDAQ:ALKS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
